ClinicalTrials.gg
CompletedNCT04128917Updated May 12, 2021

Triple Therapy With Tegoprazan in H. Pylori Positive Patients_PILOT

A Phase 3 interventional study of Tegoprazan and RAPAE01 in Helicobacter Pylori Infection, sponsored by HK inno.N Corporation. Completed at 1 site in Korea, Republic of. Open to participants aged 19 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-05-12.

Sponsored by HK inno.N Corporation · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
102
Allocation
Randomized
Ages
19 Years to 75 Years
Sex
All
01

Study summary

This study aims to compare safety and efficacy in an exploratory manner between a Tegoprazan triple therapy and a RAPAE01 triple therapy in H. pylori positive patients.

Read the detailed description

A Randomized, Double-Blind, Active-controlled, Multicenter, Pilot Study to Investigate the Safety and Efficacy of a Tegoprazan triple therapy and a RAPAE01 triple therapy in H. pylori positive patients.

02

Conditions studied

  • Helicobacter Pylori Infection
03

In context

Lead sponsor

HK inno.N Corporation is the lead sponsor of 104 studies on the registry; 19 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • H. pylori positive at screening
  • Subjects who have upper gastrointestinal disease

Exclusion criteria

Exclusion Criteria:

  • Having received prior therapy for eradication of H. pylori
  • Prior use of P-CAB, proton pump inhibitors (PPIs), H2 receptor blockers within 14 days
  • Prior use of H. pylori eradication effective antibiotics, bismuth within 28 days
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
102 participants (actual)

Study arms

  • Experimental
    Tegoprazan 50 mg

    Tegoprazan 50 mg Triple Therapy

    Drug: Tegoprazan

  • Experimental
    Tegoprazan 100 mg

    Tegoprazan 100 mg Triple Therapy

    Drug: Tegoprazan

  • Active comparator
    RAPAE01

    RAPAE01 Triple Therapy

    Drug: RAPAE01

Interventions

  • Tegoprazan 50 mg or 100 mg/Clarithromycin/Amoxicillin BID peroral

  • DrugRAPAE01

    RAPAE01/Clarithromycin/Amoxicillin BID peroral

06

What researchers measure

Primary outcomes

  1. H. pylori eradication rate

    Assess H. pylori eradication rate by UBT

    Time frame: Day 49

07

Study locations

1 site
  • Chung-Ang University Hosptial
    Seoul, Korea, Republic of
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2020 to primary completion in Dec 2020, 11 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 15, 2019
First posted
Oct 16, 2019
StartActual
Jan 21, 2020
Primary completionActual
Dec 21, 2020
CompletionActual
Jan 29, 2021
Last update
May 12, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 12, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04128917
Responsible party
Sponsor
First posted
Oct 16, 2019
Start date
Jan 21, 2020
Primary completion
Dec 21, 2020
Completion
Jan 29, 2021
Last update
May 12, 2021

Study contacts

JAEGYU KIM
principal investigator · Chung-Ang University Hosptial, Chung-Ang University College of Medicine

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tegoprazan

Start the discussion